Cell and gene therapy specialist Oxford Biomedica (LSE: OXB) has inked a new five-year collaboration deal with the not-for-profit Vaccines Manufacturing and Innovation Centre (VMIC).
The VMIC, which was established to provide the UK’s first strategic vaccine development and advanced manufacturing capability, is also based in Oxford, UK.
Both organizations are members of an Oxford University manufacturing consortium focussed on scaling-up the GMP manufacture AstraZeneca’s (LSE: AZN) COVID-19 vaccine candidate, AZD1222.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze